PDF(5088 KB)
血管内皮生长因子A对缺氧性肺动脉高压新生大鼠肺血管重塑的影响及其机制研究
曹静, 罗佳媛, 吴典, 赵倩, 李明霞
中国当代儿科杂志 ›› 2021, Vol. 23 ›› Issue (1) : 103-110.
PDF(5088 KB)
PDF(5088 KB)
血管内皮生长因子A对缺氧性肺动脉高压新生大鼠肺血管重塑的影响及其机制研究
Effect and mechanism of vascular endothelial growth factor-A on pulmonary vascular remodeling in neonatal rats with hypoxic pulmonary hypertension
目的 探讨血管内皮生长因子A（VEGF-A）调控生存素（SVV）在缺氧性肺动脉高压（HPH）新生大鼠肺血管重塑中的作用。方法 96只新生大鼠随机分为HPH+VEGF-A组、HPH组和对照组，每组再随机分为3 d、7 d、10 d和14 d亚组，每个亚组8只大鼠。HPH+VEGF-A组和HPH组分别经气管内转染携带/不携带VEGF-A的腺病毒载体后建立HPH模型，对照组气管内注射0.9% NaCl溶液后常氧下饲养。直接测压法测定新生大鼠平均右心室收缩压（RVSP）；苏木精-伊红染色后光镜下观察肺血管形态学变化，计算肺小动脉中层血管壁厚度占肺小动脉外径的百分比（MT%）和肺小动脉中层横截面积占总横截面积的百分比（MA%）；免疫组化法检测肺组织中VEGF-A和SVV的表达水平。结果 HPH组新生大鼠平均RVSP高于同时间点对照组和HPH+VEGF-A组（P < 0.05）。缺氧7 d，HPH组出现肺血管重塑，HPH+VEGF-A组自缺氧10 d开始出现。缺氧7 d时，HPH组MT%和MA%高于对照组和HPH+VEGF-A组（P < 0.05）；缺氧10 d和14 d时，HPH组及HPH+VEGF-A组MT%和MA%均高于对照组（P < 0.05）。缺氧各时间点HPH组和HPH+VEGF-A组VEGF-A表达均高于对照组（P < 0.05）；缺氧3 d和7 d时，HPH+VEGF-A组VEGF-A表达高于HPH组（P < 0.05）。缺氧14 d时，HPH组SVV表达高于对照组（P < 0.05）；缺氧各时间点HPH+VEGF-A组SVV表达均高于对照组（P < 0.05）；缺氧3 d和7 d时，HPH+VEGF-A组SVV表达高于HPH组（P < 0.05）。结论 预防性外源性气管内给予HPH新生大鼠VEGF-A，可在缺氧早期通过上调SVV表达抑制肺血管重塑，降低肺动脉压力，为新生儿HPH肺血管重塑干预治疗提供了依据。
Objective To study the role of vascular endothelial growth factor-A (VEGF-A) in pulmonary vascular remodeling in neonatal rats with hypoxic pulmonary hypertension (HPH) by regulating survivin (SVV). Methods A total of 96 neonatal rats were randomly divided into three groups: HPH+VEGF-A group, HPH group, and control group. Each group was further randomly divided into 3-, 7-, 10-, and 14-day subgroups (n=8 in each subgroup). The neonatal rats in the HPH+VEGF-A and HPH groups were intratracheally transfected with adenoviral vectors with or without VEGF-A gene respectively. Those in the control group were given intratracheal injection of normal saline and were then fed under normoxic conditions. The direct measurement method was used to measure mean right ventricular systolic pressure (RVSP). Hematoxylin-eosin staining was used to observe the morphological changes of pulmonary vessels under a light microscope and calculate the percentage of media wall thickness (MT%) and the percentage of media wall cross-sectional area (MA%) in the pulmonary arterioles. Immunohistochemistry was used to measure the expression levels of VEGF-A and SVV in lung tissue. Results The HPH group had a significantly higher mean RVSP than the control and HPH+VEGF-A groups at each time point (P < 0.05). Pulmonary vascular remodeling occurred in the HPH group on day 7 of hypoxia, while it occurred in the HPH+VEGF-A group on day 10 of hypoxia. On day 7 of hypoxia, the HPH group had significantly higher MT% and MA% than the control and HPH+VEGF-A groups (P < 0.05). On days 10 and 14 of hypoxia, the HPH and HPH+VEGF-A groups had significantly higher MT% and MA% than the control group (P < 0.05). The HPH and HPH+VEGF-A groups had significantly higher expression of VEGF-A than the control group at each time point (P < 0.05). On days 3 and 7 of hypoxia, the HPH+VEGF-A group had significantly higher expression of VEGF-A than the HPH group (P < 0.05). On day 14 of hypoxia, the HPH group had significantly higher expression of SVV than the control group (P < 0.05). The HPH+VEGF-A group had significantly higher expression of SVV than the control group at each time point (P < 0.05). On days 3 and 7 of hypoxia, the HPH+VEGF-A group had significantly higher expression of SVV than the HPH group (P < 0.05). Conclusions Prophylactic intratracheal administration of exogenous VEGF-A in neonatal rats with HPH can inhibit pulmonary vascular remodeling and reduce pulmonary arterial pressure by upregulating the expression of SVV in the early stage of hypoxia. This provides a basis for the interventional treatment of pulmonary vascular remodeling in neonatal HPH.
血管内皮生长因子 / 生存素 / 肺动脉高压 / 血管重塑 / 新生大鼠
Vascular endothelial growth factor / Survivin / Pulmonary hypertension / Vascular remodeling / Neonatal rats
[1] Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension:state of the art and research perspectives[J]. Eur Respir J, 2019, 53(1):1801887.
[2] Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension:pathogenesis and clinical management[J]. BMJ, 2018, 360:j5492.
[3] Distefano G, Sciacca P. Molecular physiopathogenetic mechanisms and development of new potential therapeutic strategies in persistent pulmonary hypertension of the newborn[J]. Ital J Pediatr, 2015, 41:6.
[4] Sakao S, Taraseviciene-Stewart L, Wood K, et al. Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth[J]. Am J Physiol Lung Cell Mol Physiol, 2006, 291(3):L362-L368.
[5] Rhodes CJ, Im H, Cao A, et al. RNA sequencing analysis detection of a novel pathway of endothelial dysfunction in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2015, 192(3):356-366.
[6] Jiang X, Li T, Sun J, et al. SETD3 negatively regulates VEGF expression during hypoxic pulmonary hypertension in rats[J]. Hypertens Res, 2018, 41(9):691-698.
[7] Star GP, Giovinazzo M, Lamoureux E, et al. Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro[J]. Life Sci, 2014, 118(2):191-194.
[8] Rafatmanesh A, Behjati M, Mobasseri N, et al. The survivin molecule as a double-edged sword in cellular physiologic and pathologic conditions and its role as a potential biomarker and therapeutic target in cancer[J]. J Cell Physiol, 2020, 235(2):725-744.
[9] Meng L, Zhu F, Zhou X, et al. Survivin is critically involved in VEGFR2 signaling-mediated esophageal cancer cell survival[J]. Biomed Pharmacother, 2018, 107:139-145.
[10] Yu L, Tu Y, Jia X, et al. Resveratrol protects against pulmonary arterial hypertension in rats via activation of silent information regulator 1[J]. Cell Physiol Biochem, 2017, 42(1):55-67.
[11] Chen M, Ding Z, Zhang F, et al. A20 attenuates hypoxia-induced pulmonary arterial hypertension by inhibiting NF-κB activation and pulmonary artery smooth muscle cell proliferation[J]. Exp Cell Res, 2020, 390(2):111982.
[12] 刘坤珍, 王乐, 李明霞. 热休克蛋白70对缺氧性肺动脉高压新生大鼠肺血管重塑的作用研究[J]. 中国当代儿科杂志, 2016, 18(2):152-158.
[13] 王乐, 吴海燕, 李明霞. 热休克蛋白70对新生大鼠缺氧性肺动脉高压的保护作用[J]. 中国当代儿科杂志, 2017, 19(1):88-94.
[14] Cao YY, Ba HX, Li Y, et al. Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats[J]. Life Sci, 2020, 250:117548.
[15] Ciuclan L, Bonneau O, Hussey M, et al. A novel murine model of severe pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2011, 184(10):1171-1182.
[16] Samuel S, Fan F, Dang LH, et al. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells[J]. Oncogene, 2011, 30(10):1205-1212.
[17] Bender RJ, Mac Gabhann F. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis[J]. BMC Syst Biol, 2015, 9:55.
[18] Park SA, Jeong MS, Ha KT, et al. Structure and function of vascular endothelial growth factor and its receptor system[J]. BMB Rep, 2018, 51(2):73-78.
[19] Sakao S, Tatsumi K. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension[J]. Respiration, 2011, 81(3):253-261.
[20] Stobiecka M, Ratajczak K, Jakiela S. Toward early cancer detection:focus on biosensing systems and biosensors for an anti-apoptotic protein survivin and survivin mRNA[J]. Biosens Bioelectron, 2019, 137:58-71.
[21] Varughese RK, Torp SH. Survivin and gliomas:a literature review[J]. Oncol Lett, 2016, 12(3):1679-1686.
[22] Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF[J]. Proc Natl Acad Sci U S A, 2002, 99(7):4349-4354.
国家自然科学基金（81760278）；新疆维吾尔自治区卫生健康青年医学科技人才专项科研项目（WJWY-201901）。
